双侧小脑高频rTMS治疗难治性癫痫:一项随机、单盲、假对照研究。
完整摘要 · 中文译文
背景:对于不适合手术的耐药性癫痫患者,经颅磁刺激(TMS)是一种重要的非侵入性神经调控疗法。小脑皮层可通过小脑-丘脑-皮层通路抑制皮层兴奋性。在此,我们探讨高频(20 Hz)小脑重复经颅磁刺激(rTMS)是否能减少难治性癫痫的发作频率和发作间期癫痫样放电(IEDs)。 方法:87例难治性癫痫患者纳入意向治疗(ITT)人群(n = 87),随后随机分配至活性rTMS组(n = 44)或假刺激组(n = 43)。治疗组中1例患者无基线后疗效数据;因此疗效分析在改良意向治疗(mITT)人群(n = 86)中进行。活性组接受两个疗程的20 Hz rTMS,靶向小脑。治疗前后评估癫痫发作频率和IEDs。 结果:泊松广义线性混合模型显示,癫痫发作频率存在显著的组×时间交互作用[F(2,236) = 162.65,p < 0.001]。活性组在第1、2、3个月的癫痫发作频率显著较低(均p < 0.001),第2个月差异最大。活性组癫痫发作频率的下降百分比分别为64.6%、73.2%和13.3%,而对照组分别为3.9%、0.6%和-8.4%(均P < 0.001)。活性组的应答率(≥50%下降)分别为90.7%、95.3%和0%,对照组为0%(第1-2个月p < 0.001)。组内分析显示s 活动性rTMS后IED显著减少(p < 0.001),而对照组无变化。此外,显著的组×基线交互作用(p < 0.001)表明基线IED较高的患者抑制程度更大。探索性亚组分析进一步证实了这一点。所有不良事件均为轻度,两组间发生率无显著差异。 结论:活动性小脑rTMS与难治性癫痫发作频率降低、应答率提高及IED抑制相关,且无明显不适。最佳疗效持续时间约为2个月,基线水平较高的患者IED抑制程度更大。
完整摘要 · 英文原文
BACKGROUND: For patients with drug-resistant epilepsy who are not suitable for surgery, transcranial magnetic stimulation (TMS) is an important non-invasive neuromodulation therapy. The cerebellar cortex can inhibit cortical excitability via the cerebello-thalamo-cortical pathway. Here, we explore whether high-frequency (20 Hz) cerebellar repetitive TMS (rTMS) reduces seizure frequency and interictal epileptiform discharges (IEDs) in refractory epilepsy. METHODS: Eighty-seven patients with refractory epilepsy were included in the intention-to-treat (ITT) population (n = 87) and then randomized to active rTMS (n = 44) or sham stimulation (n = 43). One patient in treatment group had no post-baseline efficacy data; efficacy analyses were therefore performed in the modified intention-to-treat (mITT) population (n = 86). The active group received two cycles of 20 Hz rTMS targeting the cerebellum. Seizure frequency and IEDs were assessed before and after treatment. RESULTS: Poisson generalized linear mixed models revealed a significant group×time interaction for seizure frequency [F(2,236) = 162.65, p < 0.001]. The active group had significantly lower seizure frequencies at months 1, 2, and 3 (all p < 0.001), with the largest difference at month 2. Percentage reductions of seizure frequency in the active group were 64.6%, 73.2%, and 13.3%, respectively, compared with 3.9%, 0.6%, and -8.4% in the control group (all P < 0.001). Responder rates (≥50% reduction) in the active group were 90.7%, 95.3%, and 0% vs. 0% in controls (p < 0.001 for months 1-2). Within-group analysis showed significant IED reduction after active rTMS (p < 0.001) but no change in controls. Moreover, a significant group × baseline interaction (p < 0.001) indicated greater suppression in patients with higher baseline IEDs. Exploratory subgroup analysis further confirmed this. All adverse events were mild, with no significant difference in the incidence between the two groups. CONCLUSION: Active cerebellar rTMS was associated with reduced seizure frequency, improved responder rates, and suppressed IEDs in refractory epilepsy with no obvious discomfort. The optimal efficacy duration was approximately 2 months, with greater IED suppression in patients with higher baseline levels.